Skip to content
Politically.com Search all
Menu

Final rule 2025-18082

Microbiology Devices; Reclassification of Antigen, Antibody, and Nucleic Acid-Based Hepatitis B Virus Assay Devices

The Food and Drug Administration (FDA) is issuing a final order reclassifying qualitative hepatitis B virus (HBV) antigen assays (product code LOM), HBV antibody assays (product code LOM), and quantitative HBV nucleic acid-based assays (product code MKT), all of which are postamendments class III devices, into class II (special controls), subject to premarket notification. FDA is also establishing the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of these device types.

Source: FederalRegister.gov API v1Recently refreshed. Last successful refresh: 2026-07-31 22:49:02 UTC.

Source-supplied record

Document details

Document number
2025-18082
Published
Sep 18, 2025
Effective
Oct 20, 2025
Comments close
Not supplied
Federal Register citation
90 FR 44969

Docket identifiers

  • Docket No. FDA-2024-N-3533

CFR references

  • Title 21, part 866